Primary Objectives~1. To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients with relapsed and refractory POMES Syndrome.~Secondary Objectives~To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with POMES Syndrome.~To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.